GHRS logo

GH Research PLC (GHRS)

$18.27

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on GHRS

Market cap

$1.25B

EPS

-0.79

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.315884

Price on GHRS

Previous close

$18.75

Today's open

$18.48

Day's range

$17.57 - $18.48

52 week range

$12.04 - $31.44

Profile about GHRS

CEO

Velichka Valcheva

Employees

73

Headquarters

DUBLIN 2,

Exchange

NASDAQ Global Market

Shares outstanding

68557174

Issue type

Common Stock

GHRS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on GHRS

GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update

Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visit TRD pivotal program — positive initial feedback from FDA, End-of-Phase 2 meeting expected in Q1 2027, initiation shortly after PPD pivotal program — initiation targeted for H2 2027 Vanina Popova, MD, appointed Chief Development Officer — Formerly Clinical Development at J&J, lead author of pivotal Spravato® trial publication Cash, cash equivalents and marketable securities of $350.6 million as of September 30, 2026 DUBLIN, Nov. 13, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended September 30, 2026, and provided a business update. Business Updates Global Pivotal Program of GH001 in TRD The final results of our Phase 1 trial GH001-HV-106 in healthy volunteers support one fixed dose of GH001 per treatment visit with our novel GH001 Aerosol Delivery System (ADS).

news source

GlobeNewsWire • Nov 13, 2026

news preview

GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer

DUBLIN, Nov. 13, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the appointment of Vanina Popova, MD, as Chief Development Officer, to lead the clinical development of GH001 into our pivotal programs in treatment-resistant depression (TRD) and postpartum depression (PPD).

news source

GlobeNewsWire • Nov 13, 2026

news preview

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

GH Research remains significantly undervalued due to the large unmet need in treatment-resistant depression and GH001's potential efficacy. While early data appears promising, and Eli Lilly's acquisition of AtaiBeckley validates the value of 5-MEO-DMT, GH Research still needs to generate solid Phase III data and receive FDA approval. With over 350 million USD in cash, GH Research is well positioned to commercialize GH001. Investors should be prepared for further dilution before the company becomes profitable, though.

news source

Seeking Alpha • Oct 23, 2026

news preview

GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities

I initiate coverage on GH Research PLC with a "Buy" rating, driven by renewed momentum in its GH001 program for treatment-resistant depression [TRD]. The company resolved the FDA clinical hold on its IND for GH001, positioning it for a pivotal phase 3 TRD trial expected to start in 2026. GH001 demonstrates competitive advantages: shortest-acting psychedelic [11-minute psychoactive phase] and reduced treatment visits versus SPRAVATO and BPL-003.

news source

Seeking Alpha • Sep 20, 2026

news preview

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

Alignment with FDA on CMC and device plans for Phase 3 Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials  Further strengthening of US and EU mebufotenin patent estate Phase 2a results in postpartum depression published in The Journal of Clinical Psychiatry Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026 DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a business update. Business Updates Global Pivotal Program of GH001 in TRD We have completed GH001-HV-106, our Phase 1 clinical pharmacology trial of our proprietary aerosol delivery device in healthy volunteers, and GH001-HV-109, our IND-opening Phase 1 trial of GH001 in healthy volunteers in the United States.

news source

GlobeNewsWire • Aug 6, 2026

news preview

Why Is GH Research Stock Trading Higher on Thursday?

GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher in response to Eli Lilly and Co. (NYSE:LLY) agreeing to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal valued at up to $3.80 billion.

news source

Benzinga • Jul 16, 2026

news preview

Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says

The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sciences (NEO:AWKN) and others in the sector. The firm wrote on Monday that the final guidance, alongside the FDA's plans to hold a public hearing on September 14, points to a more supportive regulatory environment that could reduce regulatory risk for psychedelic drug developers.

news source

Proactive Investors • Jul 13, 2026

news preview

GH Research Announces Publication of Phase 2a Postpartum Depression Results

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled “Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a Open-Label Clinical Trial,” has been published in The Journal of Clinical Psychiatry (DOI: 10.4088/JCP.25m16284).

news source

GlobeNewsWire • Jun 4, 2026

news preview

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While the rapid onset and short psychedelic experience duration offered by GH001 are compelling it remains to be seen how the drug stacks up against peers under real-world conditions.

news source

Seeking Alpha • May 20, 2026

news preview

These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.

news source

Benzinga • May 15, 2026

news preview

¹ Disclosures

Get started with M1

Invest in GH Research PLC

Open an M1 investment account to buy and sell GH Research PLC commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in GHRS on M1